XML 45 R23.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Share-based compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-Based Payment Arrangements [Abstract] |
Share-based compensation | Share-based compensation: The Company provides share-based compensation to its directors and certain employees through grants of stock options, TSARs, SARs and deferred, restricted or performance share units. As at December 31, 2021, the Company had 3,634,629 common shares reserved for future grants of stock options and tandem share appreciation rights under the Company’s stock option plan. a) Share appreciation rights and tandem share appreciation rights: All SARs and TSARs granted have a maximum term of seven years with one-third vesting each year from the date of grant. SARs and TSARs units outstanding at December 31, 2021 and 2020 are as follows:
| SARs |  | TSARs
| Number of units | Exercise price USD |  | Number of units | Exercise price USD
Outstanding at December 31, 2019 | 857,407 |  | $ | 52.02 |  |  | 1,661,327 |  | $ | 52.55 |
Granted | 96,160 |  | 29.27 |  | 761,050 |  | 29.27
Exercised | (20,635) |  | 34.59 |  | (1,900) |  | 34.59
Cancelled | (31,660) |  | 58.13 |  | (5,967) |  | 58.38
Expired | (60,500) |  | 38.24 |  | (74,020) |  | 38.24
Outstanding at December 31, 2020 | 840,772 |  | $ | 50.61 |  |  | 2,340,490 |  | $ | 45.43 |
Granted | 39,490 |  | 38.79 |  | 338,260 |  | 38.79
Exercised | (30,151) |  | 34.06 |  | (50,623) |  | 33.89
Cancelled | (25,100) |  | 52.34 |  | (21,460) |  | 50.98
Expired | (158,755) |  | 71.10 |  |  | (226,430) |  | 73.13 |
Outstanding at December 31, 2021 | 666,256 |  | $ | 45.70 |  |  | 2,380,237 |  | $ | 42.05 |
Information regarding the SARs and TSARs outstanding as at December 31, 2021 is as follows:
| Units outstanding at December 31, 2021 |  | Units exercisable at December 31, 2021
Range of exercise prices | Weighted average remaining contractual life (years) | Number of units outstanding | Weighted average exercise price |  | Number of units exercisable | Weighted average exercise price
SARs |  |  |  |  |  |
$29.27 to $35.51 | 2.80 | 228,520 | $ | 32.42 |  | 164,410 | $ | 33.65
$38.24 to $50.17 | 3.19 | 154,606 | 47.25 |  | 115,116 | 50.15
$54.65 to $78.59 | 1.69 | 283,130 | 55.58 |  | 274,376 | 55.52
| 2.42 | 666,256 | $ | 45.70 |  | 553,902 | $ | 47.91
TSARs |  |  |  |  |  |
$29.27 to $35.51 | 4.14 | 1,014,664 | $ | 30.64 |  | 507,288 | $ | 32.00
$38.24 to $50.17 | 4.35 | 643,244 | 44.02 |  | 297,710 | 49.94
$54.65 to $78.59 | 2.96 | 722,329 | 56.33 |  | 631,379 | 56.15
| 3.84 | 2,380,237 | $ | 42.05 |  | 1,436,377 | $ | 46.33
The fair value of each outstanding SARs and TSARs grant was estimated on December 31, 2021 and 2020 using the Black-Scholes option pricing model with the following weighted average assumptions:
| 2021 | 2020
Risk-free interest rate | 0.7% | 0.1%
Expected dividend yield | 1.3% | 0.3%
Expected life of SARs and TSARs (years) | 1.7 | 1.6
Expected volatility | 51% | 60%
Expected forfeitures | 0% | 0%
Weighted average fair value (USD per share) | $ | 8.81 |  | $ | 13.36 |
Compensation expense for SARs and TSARs is measured based on their fair value and is recognized over the vesting period. Changes in fair value in each period are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value as at December 31, 2021 was $27.8 million compared with the recorded liability of $26.1 million. The difference between the fair value and the recorded liability of $1.7 million will be recognized over the weighted average remaining vesting period of approximately 1.5 years. For the year ended December 31, 2021, compensation expense related to SARs and TSARs included a recovery in cost of sales and operating expenses of $13.5 million (2020 - expense of $33.1 million). This included a recovery of $20.5 million (2020 - expense of $27.2 million) related to the effect of the change in the Company’s share price. b) Deferred, restricted and performance share units (old plan and new plan): Deferred, restricted and performance share units (old plan and new plan) outstanding as at December 31, 2021 and 2020 are as follows:
| Number of deferred share units |  | Number of restricted share units |  | Number of performance share units (old plan) | Number of performance share units (new plan)
Outstanding at December 31, 2019 | 89,766 |  |  | 83,168 |  |  | 303,445 |  | 138,038 |
Granted | 29,393 |  |  | 154,460 |  |  | — |  | 301,090 |
Performance factor impact on redemption 1 | — |  |  | — |  |  | (117,674) |  | — |
Granted in lieu of dividends | 3,788 |  |  | 7,326 |  |  | 4,529 |  | 13,597 |
Redeemed | — |  |  | (7,713) |  |  | (39,612) |  | (1,842) |
Cancelled | — |  |  | (8,369) |  |  | (3,887) |  | (7,713) |
Outstanding at December 31, 2020 | 122,947 |  |  | 228,872 |  |  | 146,801 |  | 443,170 |
Granted | 23,384 |  |  | 132,360 |  |  | — |  | 258,970 |
Performance factor impact on redemption 1 | — |  |  | — |  |  | (110,354) |  | — |
Granted in lieu of dividends | 1,074 |  |  | 2,729 |  |  | — |  | 5,545 |
Redeemed | (13,987) |  |  | (6,103) |  |  | (36,447) |  | — |
Cancelled | — |  |  | (25,473) |  |  | — |  | (17,997) |
Outstanding at December 31, 2021 | 133,418 |  |  | 332,385 |  |  | — |  | 689,688 |
1 Performance share units granted prior to 2019 have a feature where the ultimate number of units that vest are adjusted by a performance factor of the original grant as determined by the Company's total shareholder return in relation to a predetermined target over the period to vesting. These units relate to performance share units redeemed in the quarter ended March 31, 2020, and the quarter ended March 31, 2021. Performance share units granted since 2019 reflect a new long-term incentive plan. The performance share units granted under the new plan are redeemable for cash based on the market value of the Company's common shares and are non-dilutive to shareholders. They vest over three years and include two performance factors: (i) relative total shareholder return of Methanex shares versus a specific market index (the market performance factor) and (ii) three year average Return on Capital Employed (the non-market performance factor). The market performance factor is measured by the Company at the grant date and reporting date using a Monte-Carlo simulation model to determine fair value. The non-market performance factor reflects management's best estimate to determine the expected number of units to vest. Based on these performance factors the performance share unit payout will range between 0% to 200%, with the first payout of the new performance share units in 2022. Compensation expense for deferred, restricted and performance share units is measured at fair value based on the market value of the Company’s common shares and is recognized over the vesting period. Changes in fair value are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value of deferred, restricted and performance share units as at December 31, 2021 was $52.7 million compared with the recorded liability of $42.4 million. The difference between the fair value and the recorded liability of $10.4 million will be recognized over the weighted average remaining vesting period of approximately 1.6 years. For the year ended December 31, 2021, compensation expense related to deferred, restricted and performance share units included in cost of sales and operating expenses was an expense of $12.2 million (2020 - expense of $22.0 million). This included a recovery of $2.3 million (2020 - expense of $11.4 million) related to the effect of the change in the Company’s share price. c) Stock options: The exercise price of each stock option is equal to the quoted market price of the Company’s common shares at the date of the grant. Options granted have a maximum term of seven years with one-third of the options vesting each year after the date of grant. Common shares reserved for outstanding incentive stock options as at December 31, 2021 and 2020 are as follows:
| Number of stock options | Weighted average exercise price
Outstanding at December 31, 2019 | 200,631 |  | $ | 49.07 |
Granted | 15,440 |  | 29.27 |
Exercised | (5,900) |  | 34.59 |
Cancelled | (5,600) |  | 58.96 |
Expired | (31,320) |  | 38.24 |
Outstanding at December 31, 2020 | 173,251 |  | $ | 49.44
Granted | 6,880 |  | $ | 38.79 |
Exercised | (7,300) |  | 34.59 |
Expired | (27,210) |  | 73.13 |
Outstanding at December 31, 2021 | 145,621 |  | $ | 45.25
Information regarding the stock options outstanding as at December 31, 2021 is as follows:
| Options outstanding at December 31, 2021 |  | Options exercisable at December 31, 2021
Range of exercise prices | Weighted average remaining contractual life (years) | Number of stock options outstanding | Weighted average exercise price |  | Number of stock options exercisable | Weighted average exercise price
Options |  |  |  |  |  |
$29.27 to $35.51 | 2.27 | 56,007 |  | $ | 33.12 |  | 45,713 |  | $ | 33.99
$38.24 to $50.17 | 3.06 | 30,914 |  | 47.64 |  | 24,034 |  | 50.17
$54.65 to $78.59 | 1.68 | 58,700 |  | 55.57 |  | 56,230 |  | 55.48
| 2.20 | 145,621 |  | $ | 45.25 |  | 125,977 |  | $ | 46.67
For the year ended December 31, 2021, compensation expense related to stock options was $0.1 million (2020 - $0.1 million).

X
- Definition The entire disclosure for share-based payment arrangements. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 44 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share-Based Payment Arrangements [Abstract] + References No definition available. + Details
Name: | mx_ShareBasedPaymentArrangementsAbstract
Namespace Prefix: | mx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration